Abstract:OBJECTIVE:To summarize the clinical characteristics, early diagnosis, comprehensive treatment and prognosis of 6 cases of children with post-transplantation lymphoproliferative disorder (PTLD) after liver transplantation.METHOD:Data of 6 cases with PTLD seen between January 2011 and December 2013 were retrospectively analyzed. The anti-rejection drug dose adjustments, the effect of rituximab, antiviral therapy and comprehensive treatment program after surgery were explored.RESULT:(1) The diagnosis of PTLD was confirmed by histologic findings. Six cases of PTLD including 3 males and 3 females were diagnosed as congenital biliary atresia and underwent split liver transplantation. The occurrence rate of PTLD was 2.9%. (2) The median time to the development of PTLD was less than 6 months. The initial symptom of PTLD in all patients was fever and clinical manifestations of PTLD were non-specific, depending on the involving organs. Five cases of PTLD developed gastrointestinal symptoms, including diarrhea, abdominal pain, and abdominal distension. One case developed respiratory symptoms, including cough and tachypnea. Three cases had lymph node involvement. In 2 cases pathophysiology involved polymorphic lymphocyte proliferation and in 4 cases B lymphocyte proliferation. (3) Two cases died, in whom EBV DNA was not detected and were diagnosed as PTLD by surgical pathology before death. Four survived cases had high EBV-DNA load and then were diagnosed as PTLD by biopsy pathology. (4) Of the 6 cases of PTLD, 2 cases died and 4 cases survived. The overall mortality was 33%. The dead cases were only treated with laparotomy because of intestinal obstruction or perforation and the survived cases were treated with tacrolimus at reduced doses or discontinuation and rituximab. In 2 cases antiviral therapy (acyclovir) was continued, including 1 cases of intestinal obstruction treated with surgical repair. All the survived patients were followed up for 4 months to 1 year and no evidence has been found.CONCLUSION:EBV infection is the high risk factor for PTLD after liver transplantation. Close clinical surveillance of EBV DNA for pediatric liver transplantation was important for the early diagnosis of PTLD. Reducing doses of immunosuppressive agents and rituximab is the initial therapy for PTLD. A reduction in the dose of tacrolimus is suggested. Operation therapy can also play a role in the management of local complications.

S3924 The Perfect Storm for Post Transplant Lymphoproliferative Disorder: A Case Report

Gastrointestinal Tract Post-Transplant Lymphoproliferative Disorder after Liver Transplantation

Post-transplantation Lymphoproliferative Disorder (PTLD): In the Liver Transplant Recipient

Cutaneous Post-transplant Lymphoproliferative Disorder

Post-Transplant Lymphoproliferative Disorder Presenting as a Gastrointestinal Fistulous Tract in a Heart Transplant Recipient: Case Report and Literature Review

S4392 A Rare Case of T-cell Post-Transplant Lymphoproliferative Disorder (PTLD) Found Following a Diagnosis of Hemophagocytic Lymphohistiocytosis in a Patient With History of Liver Transplantation

S4545 Simultaneous Presentation of Post-Transplant Lymphoproliferative Disorder (PTLD) and Acute Cellular Rejection (ACR) in a Liver Transplant Recipient: A Therapeutic Conundrum

Case Report: Post-transplant lymphoproliferative disorder as a serious complication of vascularized composite allotransplantation

S1101 Surgical Outcomes Following an Episode of Acute Severe Ulcerative Colitis: A Single Center Cohort Study

S2865 A Case of Undifferentiated Colitis in a Patient With Liver Transplant and Crohn's Disease

Infectious complications during immunochemotherapy of post-transplantation lymphoproliferative disease–can we decrease the risk? Two case reports and review of literature

Admissions for posttransplant lymphoproliferative disorder: a 9-year longitudinal analysis of the National (Nationwide) Inpatient Sample

P924 Function and outcomes of ileal-pouch anal anastomosis in patients with connective tissue disorders

[The Risk Factors of Post-Transplant Lymphoproliferative Disorders Following Haploidentical Hematopoietic Stem Cell Transplantation].

Post-Transplant Lymphoproliferative Disorders (Review for Seminars in Nephrology )

A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis

S2564 Deciphering Deception: Pancreatic Mass Presenting as Post-Transplant Lymphoproliferative Disorder

Incidence, Risk Factors, and Outcomes of Pouchitis and Pouch-Related Complications in Patients With Ulcerative Colitis

S1334 Primary Prophylaxis Reduces Risk of Pouchitis Among Patients with IPAA and Primary Sclerosing Cholangitis

[Early Diagnosis and Comprehensive Treatments of Post-Transplantation Lymphoproliferative Disorder after Pediatric Liver Transplantation].

Acute lymphoblastic leukemia with pneumatosis cystoides intestinalis after hematopoietic stem cell transplantation: a case report